The latest update is out from Revance Therapeutics (RVNC).
Revance Therapeutics, Inc. has extended its agreement with Ajinomoto Bio-Pharma Services until December 31, 2027, for manufacturing services related to DAXXIFY® at their San Diego facility, with updated terms regarding product conformity and delay remedies. Additionally, the company’s President, Mr. Sjuts, will step down, receiving a severance package, which includes 18 months of his base salary and health benefits, and will remain as a consultant for a year to ensure a smooth transition and allow his equity awards to continue vesting.
For an in-depth examination of RVNC stock, go to TipRanks’ Stock Analysis page.